Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.5 USD | -2.73% | +17.41% | +47.06% |
May. 03 | Sector Update: Health Care Stocks Mixed in Afternoon Trading | MT |
May. 03 | Tandem Diabetes Care Shares Rise After Q1 Net Loss Shrinks, Sales Rise; Q2, 2024 Sales Guidance Set | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- With an enterprise value anticipated at 3.06 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+47.06% | 2.89B | B | ||
-4.02% | 184B | C+ | ||
-0.75% | 108B | C | ||
-2.97% | 67.82B | A | ||
+4.48% | 51.05B | B- | ||
+9.09% | 44.67B | B- | ||
+3.63% | 41.78B | B+ | ||
+3.12% | 26.78B | B | ||
+4.10% | 26.59B | A- | ||
+15.21% | 25.86B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TNDM Stock
- Ratings Tandem Diabetes Care, Inc.